{"id":"W2308659819","doi":"10.1038/bjc.2016.41","title":"Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer","year":2016,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":163,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre for Drug Research and Development","funders":"Cancer Research UK","keywords":"PARP inhibitor; Medicine; BRCA mutation; Ovarian cancer; Tolerability; Breast cancer; Olaparib; Dosing; Cancer; Pharmacodynamics; Internal medicine; Oncology; Pharmacology; Cancer research; Adverse effect; Pharmacokinetics; Biology; Poly ADP ribose polymerase; Polymerase; Genetics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002730495,0.0001752912,0.0005005713,0.0001226811,0.0000871657,0.00004511733,0.00007581405,0.00007880195,0.00006855121],"category_scores_gemma":[0.0001432379,0.0001222813,0.00007564681,0.0001980418,0.0004322285,0.00034429,0.00002684691,0.0002887858,6.854253e-8],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000270149,"about_ca_system_score_gemma":0.0005542258,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001041992,"about_ca_topic_score_gemma":0.001266639,"domain_scores_codex":[0.9983014,0.0001223088,0.0007276324,0.0002204843,0.0003823999,0.0002457003],"domain_scores_gemma":[0.9984043,0.00009379861,0.0008391702,0.0001107175,0.000331569,0.0002204589],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.02361539,0.0002839403,0.03196968,0.0001412529,0.0002258947,0.0002467998,0.00105291,0.00002024099,0.147402,0.00001341315,0.00008402502,0.7949444],"study_design_scores_gemma":[0.5963979,0.002160006,0.1447769,0.0494091,0.0006790414,0.009587632,0.002314957,0.0002657317,0.1927897,0.0001426002,0.000816035,0.0006603719],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9789053,0.01539044,0.0001255769,0.004268816,0.0005764398,0.0005031211,0.0002130648,0.000008042928,0.000009257476],"genre_scores_gemma":[0.9960165,0.001993957,0.0007208118,0.0004442287,0.0007220061,0.00003331871,0.000001698891,0.00003108409,0.00003641436],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.794284,"threshold_uncertainty_score":0.4986486,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01034263473245879,"score_gpt":0.3000696872213802,"score_spread":0.2897270524889214,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}